News
Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
MyChesCo on MSN19h
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH CirrhosisCONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...
5don MSN
We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are ...
Asianet Newsable on MSN1d
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On StockDespite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive ...
Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...
Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...
Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...
The company’s flagship product, Rezdiffra, has shown strong commercial performance since its FDA approval in March 2024, becoming the first approved therapy for F2-F3 MASH in the U.S. In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback